Company description

CRNX, also known as Crinetics Pharmaceuticals, is a biotechnology company that focuses on developing novel therapeutics targeting rare endocrine diseases and endocrine-related tumors. Their main goal is to provide treatments for patients with unmet medical needs. The company was founded in 2008 and went public in 2018, with its headquarters located in San Diego, California. Their pipeline of products includes small molecule drugs and biologic therapies that are in various stages of clinical development. Their lead drug candidate, paltusotine, is currently in Phase 3 clinical trials for the treatment of acromegaly and neuroendocrine tumors. In addition to paltusotine, CRNX also has multiple other drug candidates in different stages of development for rare endocrine diseases such as Cushing's disease, congenital hyperinsulinism, and polycystic ovary syndrome. The company prides itself on its team of experienced scientists and executives who have a proven track record in developing successful therapies for rare diseases. With a strong focus on innovation and patient-centered approaches, CRNX aims to bring much-needed treatments to patients with rare endocrine diseases and make a positive impact on their lives.